GO:0099553 trans-synaptic signaling by endocannabinoid, modulating synaptic transmission: Synaptic Plasticity Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0099553 describes retrograde cell-cell signaling in which endocannabinoids released from the postsynapse act on presynaptic receptors to modulate synaptic transmission.
• The endocannabinoid system is highly expressed in the basal ganglia and mesolimbic reward system, where it regulates motor control, motivation, and reward-related behaviors.
• Endocannabinoid signaling modulates neurotransmitter release probability and is a core mechanism of short-term and long-term synaptic plasticity.
• Dysregulation of this process is implicated in neurological and psychiatric disorders including addiction, Parkinson's disease, and anxiety-related behaviors.
• Cyclooxygenase-2 (COX-2) can oxygenate endocannabinoids, linking this signaling pathway to neuroinflammation and neuronal homeostasis.
• CRISPR-based knockout, point-mutation, and knock-in models of endocannabinoid pathway genes enable causal dissection of this signaling process in vitro and in vivo.
Description
Trans-synaptic signaling by endocannabinoid, modulating synaptic transmission (GO:0099553) is a biological process in which endocannabinoid ligands are released from the postsynapse and act on presynaptic receptors to regulate synaptic strength. This retrograde signaling mechanism allows the postsynaptic neuron to dynamically control its own inputs, a form of synaptic plasticity essential for information processing in the brain. The endocannabinoid system is particularly enriched in the basal ganglia and mesolimbic reward system, where it influences motor function, reward processing, and emotional states. Understanding GO:0099553 is therefore critical for researchers studying synaptic physiology, neural circuit function, and the pathophysiology of neurological and psychiatric disorders. The process also intersects with inflammatory signaling, as cyclooxygenase-2 (COX-2) can metabolize endocannabinoids and thereby influence neuronal homeostasis, memory, and anxiety-like behaviors. This article provides a research-grade overview of the molecular players, regulatory mechanisms, disease relevance, and experimental models used to study GO:0099553.
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission At A Glance
| GO ID | GO:0099553 |
|---|---|
| GO term | trans-synaptic signaling by endocannabinoid, modulating synaptic transmission |
| Ontology | biological_process |
| Synonym | none |
| Major function | Retrograde synaptic signaling that modulates neurotransmitter release and synaptic plasticity |
| Key ligands | Endocannabinoids such as anandamide and 2-arachidonoylglycerol (2-AG) |
| Major receptors | Cannabinoid receptor 1 (CB1) on presynaptic terminals |
| Primary brain regions | Basal ganglia and mesolimbic reward system |
| Associated enzymes | Cyclooxygenase-2 (COX-2) can oxygenate endocannabinoids |
What Is GO:0099553?
GO:0099553 is defined as cell-cell signaling between the presynapse and postsynapse, via the release and reception of endocannabinoid ligands, that modulates the synaptic transmission properties of the synapse. In simpler terms, it is a retrograde synaptic signaling process where the postsynaptic cell releases endocannabinoid molecules that travel backward to the presynaptic terminal and adjust how much neurotransmitter is released.
Why Is trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Important in Cell Biology?
GO:0099553 is important because it represents a fundamental mechanism by which neurons dynamically regulate synaptic strength in an activity-dependent manner. This retrograde signaling process is central to synaptic plasticity, learning, memory, and reward processing, and its dysfunction is linked to major neurological and psychiatric conditions such as addiction, Parkinson's disease, and anxiety disorders. Moreover, the intersection of endocannabinoid signaling with COX-2-mediated pathways highlights its relevance to neuroinflammation and neuronal homeostasis.
• Regulates neurotransmitter release probability and short-term synaptic plasticity.
• Enables retrograde signaling from postsynapse to presynapse, a key form of synaptic modulation.
• Highly expressed in basal ganglia, influencing motor control and habit formation.
• Central to mesolimbic reward circuitry, affecting motivation and reward-related behaviors.
• Implicated in psychiatric disorders including addiction and anxiety.
• Linked to neurological disorders such as Parkinson's disease.
• Interacts with neuroinflammatory pathways via COX-2-mediated endocannabinoid metabolism.
• Provides a target for therapeutic modulation of synaptic transmission.
• Essential for understanding circuit-level information processing and plasticity.
• Offers a model system for studying retrograde lipid signaling in the brain.
What Happens During trans-synaptic signaling by endocannabinoid, modulating synaptic transmission?
Postsynaptic endocannabinoid synthesis and release
In simple terms: The receiving neuron makes and releases endocannabinoid molecules.
Upon postsynaptic depolarization or activation of Gq-coupled receptors, endocannabinoids such as anandamide and 2-arachidonoylglycerol (2-AG) are synthesized on demand in the postsynaptic neuron and released into the synaptic cleft. This release is the first step in the retrograde signaling cascade that defines GO:0099553.
Presynaptic CB1 receptor activation
In simple terms: The released endocannabinoids bind to receptors on the sending neuron.
Endocannabinoids diffuse retrogradely and bind to cannabinoid receptor 1 (CB1), a Gi/o-coupled receptor enriched on presynaptic terminals. CB1 activation triggers downstream signaling that inhibits adenylyl cyclase and modulates ion channels, thereby reducing neurotransmitter release probability.
Modulation of neurotransmitter release
In simple terms: The sending neuron releases less neurotransmitter.
CB1 receptor activation leads to suppression of presynaptic calcium influx and inhibition of vesicle fusion machinery, resulting in decreased neurotransmitter release. This modulation alters the strength of synaptic transmission and is a hallmark of endocannabinoid-mediated synaptic plasticity.
Integration with synaptic plasticity
In simple terms: The synapse changes its strength based on this signaling.
Endocannabinoid-mediated retrograde signaling can induce short-term depression (DSE/DSI) and long-term depression (LTD) at excitatory and inhibitory synapses. These forms of plasticity are critical for circuit refinement and behavioral adaptation, particularly in basal ganglia and mesolimbic circuits.
Metabolic regulation by COX-2
In simple terms: Enzymes can break down or modify endocannabinoids.
Cyclooxygenase-2 (COX-2) can oxygenate endocannabinoids, producing prostaglandin-like metabolites that may influence neuronal homeostasis and synaptic function. This metabolic pathway adds a layer of regulation to GO:0099553 and links it to neuroinflammatory processes.
Key Genes Involved in GO:0099553 trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
The following genes and proteins are core components or regulators of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission (GO:0099553).
| Gene | Major Role | Research Relevance |
|---|---|---|
| CNR1 | Encodes cannabinoid receptor 1 (CB1), the primary presynaptic receptor for endocannabinoids | Target for knockout and point-mutation studies of retrograde signaling |
| DAGLA | Diacylglycerol lipase alpha, synthesizes 2-AG in the postsynapse | Knockout models reveal role in endocannabinoid production |
| DAGLB | Diacylglycerol lipase beta, alternative 2-AG synthesizing enzyme | Potential redundancy studies with DAGLA |
| NAPE-PLD | N-acyl phosphatidylethanolamine phospholipase D, synthesizes anandamide | Knockout affects anandamide levels and behavior |
| FAAH | Fatty acid amide hydrolase, degrades anandamide | Inhibition elevates endocannabinoid tone |
| MGLL | Monoacylglycerol lipase, degrades 2-AG | Knockout increases 2-AG and alters synaptic plasticity |
| PTGS2 | Cyclooxygenase-2, oxygenates endocannabinoids | Links endocannabinoid signaling to neuroinflammation |
| GNAI1 | Gi/o subunit coupled to CB1 | Knockout disrupts presynaptic inhibition |
| GNAO1 | Go subunit enriched in neurons, coupled to CB1 | Point mutations linked to neurological disorders |
| CACNA1B | N-type calcium channel inhibited by CB1 | Knockout reduces endocannabinoid-mediated suppression of release |
| KCNJ3 | GIRK1 potassium channel activated by CB1 | Modulates presynaptic excitability |
| KCNJ6 | GIRK2 potassium channel activated by CB1 | Knockout alters inhibitory signaling |
| GRM5 | Metabotropic glutamate receptor 5, stimulates 2-AG synthesis | Knockout impairs endocannabinoid-dependent LTD |
| PLCB1 | Phospholipase C beta 1, downstream of Gq-coupled receptors | Required for activity-dependent 2-AG production |
| ITPR1 | Inositol 1,4,5-trisphosphate receptor, calcium release | Modulates endocannabinoid synthesis |
| MAPK3 | ERK1, downstream of CB1 signaling | Knockout affects long-term plasticity |
| MAPK1 | ERK2, downstream of CB1 signaling | Point mutations alter signaling output |
| ADCY1 | Adenylyl cyclase 1, inhibited by CB1 | Knockout changes cAMP dynamics |
How Is trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Regulated?
The process of trans-synaptic signaling by endocannabinoid, modulating synaptic transmission is regulated at multiple levels. Endocannabinoid synthesis is activity-dependent and requires postsynaptic depolarization or Gq-coupled receptor activation. Degradation enzymes such as FAAH and MGLL tightly control ligand levels, and their inhibition enhances endocannabinoid tone. Additionally, COX-2 can oxygenate endocannabinoids, providing an alternative metabolic route that links this signaling to neuroinflammatory pathways. Presynaptic CB1 receptor desensitization and internalization also modulate the duration and magnitude of signaling.
trans-synaptic signaling by endocannabinoid, modulating synaptic transmission and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CNR1 | Addiction, Parkinson's disease | Conditional knockout mouse, point-mutation knock-in |
| PTGS2 | Neuroinflammation, anxiety, memory impairment | Overexpression and knockout cell models |
| FAAH | Anxiety, pain | Knockout mouse, enzyme inhibitor studies |
| MGLL | Neuropathic pain, inflammation | Knockout and point-mutation models |
| DAGLA | Epilepsy, synaptic plasticity deficits | Knockout and tagged knock-in |
Neurological and Psychiatric Disorders
Dysregulation of endocannabinoid signaling in the basal ganglia and mesolimbic reward system is implicated in neurological and psychiatric disorders including Parkinson's disease, addiction, and mood disorders. Altered CB1 receptor function and endocannabinoid levels have been observed in these conditions, making GO:0099553 a key pathway for therapeutic targeting.
Neuroinflammation and COX-2
Cyclooxygenase-2 (COX-2) oxygenates endocannabinoids, and this metabolic interaction links GO:0099553 to neuroinflammatory processes. COX-2 activity beyond neuroinflammation contributes to neuronal homeostasis, memory, and anxiety-like behaviors, suggesting that endocannabinoid metabolism by COX-2 may influence these functions.
Anxiety and Memory
Brain COX-2 plays a role in neuronal homeostasis underlying memory and anxiety, and its interaction with endocannabinoid signaling may modulate these behaviors. This positions GO:0099553 as a potential node for understanding stress-related and cognitive disorders.
From trans-synaptic signaling by endocannabinoid, modulating synaptic transmission-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CB1 receptor impair retrograde signaling? | CNR1 knockout cell line and mouse |
| Does a point mutation in GNAO1 alter presynaptic inhibition? | GNAO1 point-mutation knock-in |
| Can we visualize endocannabinoid release in real time? | Tagged knock-in of DAGLA or NAPE-PLD |
| Does COX-2 overexpression affect endocannabinoid tone? | PTGS2 overexpression cell model |
| Does MGLL deletion enhance 2-AG signaling? | MGLL knockout mouse and cell line |
| Can we screen for modulators of endocannabinoid signaling? | CRISPR library screening in neuronal cells |
How to Study the trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Synaptic currents and plasticity | DSE/DSI and LTD recordings |
| Mass spectrometry lipidomics | Endocannabinoid levels | Quantification of anandamide and 2-AG |
| Calcium imaging | Presynaptic calcium transients | Real-time signaling dynamics |
| Fluorescent biosensors | Neurotransmitter release | Live-cell imaging of synaptic activity |
| CRISPR knockout screening | Gene requirement for signaling | Identification of novel pathway components |
| RNA-seq | Transcriptional changes | Profiling gene expression after pathway manipulation |
| Proteomics | Protein interactions and abundance | Mapping CB1 receptor complexes |
| Behavioral assays | Reward, anxiety, motor function | Phenotyping knockout and knock-in models |
Electrophysiology
Patch-clamp recordings of excitatory and inhibitory postsynaptic currents (EPSCs/IPSCs) are used to measure endocannabinoid-mediated short-term depression (DSE/DSI) and long-term depression (LTD). These methods directly assess the functional output of GO:0099553.
Lipidomics and Mass Spectrometry
Quantification of endocannabinoids such as anandamide and 2-AG by mass spectrometry allows researchers to measure ligand levels in tissue or cell culture. This is essential for linking synthesis and degradation enzymes to signaling output.
Fluorescent Imaging and Biosensors
Genetically encoded fluorescent biosensors and calcium imaging can monitor presynaptic calcium dynamics and neurotransmitter release in real time. These tools help visualize the spatiotemporal aspects of retrograde signaling.
CRISPR-Based Genetic Screens
Pooled CRISPR knockout or activation screens in neuronal cell lines can identify novel regulators of endocannabinoid signaling. Hits can be validated by electrophysiology and lipidomics.
How CRISPR Can Be Used to Study GO:0099553 trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
Knockout
CRISPR knockout of genes such as CNR1, DAGLA, or MGLL in neuronal cell lines or primary neurons enables loss-of-function studies to determine their requirement for endocannabinoid-mediated synaptic modulation. Knockout models can be validated by electrophysiology and lipidomics.
Point Mutation
Point mutations in genes like GNAO1 or MAPK1 can be introduced to dissect specific signaling residues or disease-associated variants. These models help distinguish between distinct downstream branches of CB1 signaling.
Knock-in
Knock-in of tagged versions of DAGLA or NAPE-PLD allows visualization and affinity purification of endocannabinoid synthesis machinery. This approach provides spatial and temporal resolution of ligand production.
Overexpression
Overexpression of PTGS2 (COX-2) or CB1 can be used to study gain-of-function effects on endocannabinoid metabolism and synaptic transmission. Overexpression models are useful for testing pharmacological interventions.
How EDITGENE Supports trans-synaptic signaling by endocannabinoid, modulating synaptic transmission Research
Researchers studying trans-synaptic signaling by endocannabinoid, modulating synaptic transmission-related genes often need to determine whether a candidate gene is causally involved in ligand synthesis, receptor activation, or downstream modulation of neurotransmitter release. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for trans-synaptic signaling by endocannabinoid, modulating synaptic transmission research.
Frequently Asked Questions About trans-synaptic signaling by endocannabinoid, modulating synaptic transmission
What is GO:0099553?
GO:0099553 is the Gene Ontology term for trans-synaptic signaling by endocannabinoid, modulating synaptic transmission, a retrograde signaling process where postsynaptic endocannabinoids regulate presynaptic neurotransmitter release.
What genes are involved in trans-synaptic signaling by endocannabinoid?
Key genes include CNR1 (CB1 receptor), DAGLA and DAGLB (2-AG synthesis), NAPE-PLD (anandamide synthesis), FAAH and MGLL (degradation), and PTGS2 (COX-2).
How does endocannabinoid signaling modulate synaptic transmission?
Endocannabinoids released from the postsynapse bind presynaptic CB1 receptors, which inhibit calcium influx and reduce neurotransmitter release, thereby modulating synaptic strength.
What diseases are associated with endocannabinoid signaling dysfunction?
Dysregulation is implicated in addiction, Parkinson's disease, anxiety, and neuroinflammatory conditions involving COX-2.
What is the role of COX-2 in endocannabinoid signaling?
COX-2 can oxygenate endocannabinoids, linking this signaling pathway to neuroinflammation and neuronal homeostasis.
Which brain regions are most relevant to GO:0099553?
The basal ganglia and mesolimbic reward system show high expression of endocannabinoid system components.
How can I study endocannabinoid-mediated synaptic plasticity?
Electrophysiology, lipidomics, calcium imaging, and CRISPR-based genetic screens are commonly used.
What CRISPR models are available for endocannabinoid research?
Knockout, point-mutation, knock-in, and overexpression models for genes like CNR1, DAGLA, MGLL, and PTGS2.
Is GO:0099553 a biological process or molecular function?
GO:0099553 is a biological_process term in the Gene Ontology.
What are the main endocannabinoid ligands?
Anandamide and 2-arachidonoylglycerol (2-AG) are the primary endocannabinoid ligands.
Conclusion
GO:0099553, trans-synaptic signaling by endocannabinoid, modulating synaptic transmission, is a fundamental retrograde signaling process that shapes synaptic plasticity in the basal ganglia and mesolimbic reward system. Its dysregulation contributes to neurological and psychiatric disorders, and its intersection with COX-2-mediated metabolism links it to neuroinflammation. CRISPR-based models of key genes such as CNR1, DAGLA, MGLL, and PTGS2 provide powerful tools to dissect this pathway and identify therapeutic targets.
References
- 1. van der Stelt M et al.. 2003. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.. Eur J Pharmacol 480(1-3):133-50 PMID: 14623357
- 2. López DE et al.. 2020. The Role of Brain Cyclooxygenase-2 (Cox-2) Beyond Neuroinflammation: Neuronal Homeostasis in Memory and Anxiety.. Mol Neurobiol 57(12):5167-5176 PMID: 32860157
